Rapport Therapeutics Reports Updated Phase 2a Data for Seizure Drug RAP-219 on December 05, 2025 clinical seizure Epilepsy focal onset seizures meeting Phase 2a trial Phase 3 trials RAP-219 Rapport Therapeutics seizure drug United States Food and Drug Administration +
Meeting on the Mesa 2025 Arrives Amid Mixed Signals for Cell and Gene Therapy Sector on October 06, 2025 advanced therapies Alternative Cells Clinical Trials commercialization Gene Modification gene therapy Industry meeting MESA partnerships payment Phoenix Arizona regulatory challenges RNA, Messenger Study models +
FDA Vaccine Advisory Committee to Determine 2025-2026 COVID-19 Vaccine Formulation on May 08, 2025 Advisory Committees COVID19 (disease) Formula - diet meeting strain selection United States Food and Drug Administration Vaccines VRBPAC +